Biotech Business - July 27, 2026
Alligator discontinues independent development of mitazalimab
The Board of Directors of Alligator Bioscience has resolved to discontinue further independent development of mitazalimab and to strategically refocus the company’s resources on the out-licensed HLX22 project.
Biotech Business - July 10, 2026
Biovica refocuses US strategy and terminates agreement with Tempus AI
Biovica has, by mutual agreement, ended the reference laboratory agreement with Tempus AI, announced in May 2025.
Biotech Business - July 1, 2026
Alzinova signs Letter of Intent with Fujirebio
Alzinova has entered into a non-binding Letter of Intent with Fujirebio, a global provider of in vitro diagnostic solutions, regarding the potential development and commercialization of a blood-based diagnostic test for Alzheimer’s disease based on Alzinova’s Aβ42CC oligomer technology.
Biotech Business - June 30, 2026
Rayca Precision enters partnership with Data Powered Therapeutics
The companies have announced a strategic co-development partnership to design and advance a new generation of nanobody therapeutics for cancers of high unmet need.
Biotech Business - June 29, 2026
Cantargia announces outcome in rights issue
The board of directors of Cantargia has announced the outcome of the rights issue of shares that was announced on 28 May 2026.
Biotech Business - June 23, 2026
Combotope Therapeutics enters into collaboration with Boehringer Ingelheim
The partnership will leverage Combotope’s SMART-Phage platform to generate highly tumor-selective antibodies for next-generation cancer therapies.
